Rituximab combination therapy in relapsing multiple sclerosis
نویسندگان
چکیده
منابع مشابه
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes. METHODS In a phase 2, double-blind, 48-week trial involving 104 patients with relapsing-remitting multiple sclerosis, we assigned 69 patients to receive 1...
متن کاملOral laquinimod therapy in relapsing multiple sclerosis.
BACKGROUND Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS. Early treatment reduces the number of relapses, limits progression of disability, and improves quality of life; however, existing therapies are only partially effective and require parenteral administration. OBJECTIVE To review current experience with laquinimod as a novel immunomodulatory therapy for MS. RESULTS...
متن کاملRituximab in multiple sclerosis
OBJECTIVE To investigate the safety and efficacy of rituximab in multiple sclerosis (MS). METHODS In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminolog...
متن کاملAlemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for...
متن کاملcombination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: a preliminary clinical study
normal 0 false false false en-us x-none ar-sa microsoftinternetexplorer4 background: the efficacy of mitoxantrone induction therapy in rapidly worsening multiple sclerosis (ms) is well established. plasma exchange is also applied as an adjuvant in exacerbations of relapsing ms. the aim of this study was to compare the efficacy of combination therapy with mitoxantrone and plasma exchange versus ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Neurological Disorders
سال: 2012
ISSN: 1756-2864,1756-2864
DOI: 10.1177/1756285612461165